Delving into the Latest Updates on Mosunetuzumab with Synapse

RegulationPriority Review (United States), Breakthrough Therapy (United States), Accelerated Approval (United States), Orphan Drug (United States), Orphan Drug (European Union), Priority Review (China), Conditional marketing approval (European Union), Conditional marketing approval (China)

Login to view timeline

Structure/Sequence

Sequence Code 31212L

Source: *****

Sequence Code 616715439H

Source: *****

Sequence Code 616715440L

Source: *****

Sequence Code 651228354H

Source: *****

This phase II trial tests how well pirtobrutinib and mosunetuzumab work in treating patients with grade 1-3a follicular lymphoma (FL) that has come back after a period of improvement (relapsed) or that has not responded to previous treatment (refractory). Pirtobrutinib, a type of tyrosine kinase inhibitor, works by blocking the action of the Bruton tyrosine kinase (BTK) protein. The BTK protein signals cancer cells to multiply, and blocking it may help keep cancer cells from growing. It could also improve T cell fitness and decrease inflammation, therefore, may improve the efficacy and safety of T cell-based therapies, such as mosunetuzumab. Mosunetuzumab is a bispecific antibody that binds both T cells and the lymphoma cancer cells and harnesses T cells to interfere with the ability of cancer cells to grow and spread. Giving pirtobrutinib and mosunetuzumab together may kill more tumor cells in patients with relapsed or refractory grade 1-3a FL and potentially decreases some side effects of mosunetuzumab which are related to T cells being activated (e.g., cytokine release syndrome).

Start Date14 Nov 2025

Sponsor / Collaborator

University of Washington

[+1]

NCT07191249

/ Not yet recruitingPhase 2IIT

A Phase 2, Multicenter, Open-Label Trial to Evaluate Efficacy and Safety of Subcutaneous (SC) Mosunetuzumab in Previously Untreated Low Tumor Burden Follicular Lymphoma (LTB-FL).

This is a multi-center, open-label, interventional clinical trial designed to evaluate the efficacy and safety of subcutaneous (SC) Mosunetuzumab as a first-line immunotherapy in patients with low tumor burden follicular lymphoma (LTB-FL), defined by the absence of GELF criteria.
Eligible patients will undergo screening and, upon signing an Informed Consent Form, will receive their first dose of SC Mosunetuzumab.
Mosunetuzumab is administered via SC injection without the need for mandatory hospitalization. The first cycle lasts 21 days, followed by subsequent 28-day cycles. In Cycle 1, Mosunetuzumab is given on Day 1 (5 mg), Day 8 (45 mg), and Day 15 (45 mg). From Cycle 2 onward, a single 45 mg dose is administered on Day 1 of each cycle. Treatment continues for up to 8 cycles (approximately 6 months).
Patients will be monitored for disease status according to standard clinical practice. After completing active treatment, they will enter a post-treatment follow-up phase. Premedication with dexamethasone (20 mg) is mandatory in Cycle 1 and optional in later cycles. Acetaminophen and diphenhydramine may also be administered.
All patients will continue study treatment as per the Schedule of Activities or until premature discontinuation. After treatment discontinuation, disease status assessments will occur approximately every 3 months for up to 24 months. During post-treatment follow-up, PET-CT scans for disease evaluation will be performed every 6 months, as applicable. Patients not under active follow-up will be contacted annually to collect data on disease status and survival.
Throughout the trial, the following data will be collected (as applicable): demographics and baseline characteristics (including sex, age, race, height, and weight), medical history, details of initial diagnosis and treatment history, concomitant medications, adverse events (AEs), serious adverse events (SAEs), disease response, and survival status.

Start Date10 Oct 2025

Sponsor / Collaborator

Tel Aviv Sourasky Medical Center

[+1]

NCT06594939

/ Not yet recruitingPhase 2IIT

Multicenter Phase II Study of Mosunetuzumab and Polatuzumab Vedotin With Split-Dose CHP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma

This single-arm, interventional phase 2 study is designed to evaluate whether the inclusion of mosunetuzumab subcutaneous and polatuzumab vedotin (Mosun-Pola) to a split-dose CHP chemotherapy backbone will improve outcomes for elderly patients with a new diagnosis of diffuse large B-cell lymphoma.

Start Date01 Oct 2025

Sponsor / Collaborator

Medical College of Wisconsin

100 Clinical Results associated with Mosunetuzumab

Login to view more data

100 Translational Medicine associated with Mosunetuzumab

Login to view more data

100 Patents (Medical) associated with Mosunetuzumab

Login to view more data

103

Literatures (Medical) associated with Mosunetuzumab

13 Oct 2025·Oncoscience

Targeted therapies and resistance mechanisms in lymphoma: Current landscape and emerging solutions

Review

Author: Afshan, Roshan ; Sridhar, Shruthi ; Tiwari, Bishal

Lymphomas represent a diverse group of hematologic malignancies with variable clinical behavior and underlying biology. The fifth edition of the WHO classification (WHO-HAEM5, 2022) provides an updated, lineage-based framework to categorize lymphoid neoplasms, integrating immunophenotypic, genetic, and clinical features. With advancements in molecular profiling and immunotherapy, targeted treatments have transformed the therapeutic landscape of both Hodgkin and non-Hodgkin lymphomas. This review delineates the critical role of cell surface and intracellular receptors-including CD19, CD20, CD30, PD-1, and CCR4-in lymphoma pathogenesis and as therapeutic targets. We comprehensively evaluate FDA-approved targeted agents, including monoclonal antibodies (rituximab, brentuximab vedotin, obinutuzumab, mogamulizumab), immune checkpoint inhibitors (nivolumab, pembrolizumab), CAR T-cell therapies (axi-cel, tisa-cel, liso-cel, brexu-cel), bispecific T-cell engagers (mosunetuzumab, epcoritamab), and small-molecule inhibitors (ibrutinib, idelalisib, venetoclax). Each class is appraised for mechanism of action, efficacy, and safety in key lymphoma subtypes. Despite significant progress, therapeutic resistance remains a major obstacle. We categorize resistance mechanisms as antigen loss or modulation, pathway reactivation, immune microenvironment adaptation, and genetic/epigenetic evolution. Examples include CD19 antigen loss post-CAR-T therapy, BTK mutations conferring ibrutinib resistance, and immune checkpoint upregulation impairing T-cell function. Emerging strategies to counteract resistance include rational combination therapies, dual-targeted CAR constructs, next-generation bispecific antibodies, and precision-guided immunotherapy. Integration of biomarker profiling, real-time resistance monitoring, and novel immune-engineering approaches offers potential to overcome current therapeutic limitations. In conclusion, understanding the molecular basis of lymphoma and resistance mechanisms is critical to optimizing targeted therapy. This review synthesizes current evidence to inform clinical decision-making and outlines future directions for durable, personalized lymphoma care.

01 Oct 2025·CLINICAL PHARMACOLOGY & THERAPEUTICS

Tocilizumab Dosing for Management of T Cell‐Engaging Bispecific Antibody‐Related CRS in Patients With R/R B‐Cell NHL

Article

Author: Lundberg, Linda ; Kwan, Antonia ; Pereira, Leonardo Roque ; Guerini, Elena ; Li, Feifei ; Gibiansky, Leonid ; Turner, David C. ; Menuet, Jean‐Francois ; Jamois, Candice ; Frey, Nicolas ; Carlile, David J. ; Wei, Michael C. ; Grange, Susan ; Relf, James

The recent surge in T‐cell‐engaging and chimeric antigen receptor (CAR) T‐cell therapies is changing the landscape of cancer therapy. Cytokine release syndrome (CRS) is a systemic inflammatory response syndrome that is a well‐known complication of these therapies, of which interleukin‐6 (IL‐6) is a key mediator. Tocilizumab, an IL‐6 receptor (IL‐6R) antagonist, is approved for the management of CAR T‐cell therapy‐induced CRS in adults and in pediatric patients aged ≥ 2 years old. However, the approved dosing schedule was not based on IL‐6R occupancy and may not be the most suitable schedule for T‐cell‐engaging therapies such as bispecific antibodies (bsAb) due to key differences in the levels of released IL‐6, the clinical symptomatology of CRS, and the pharmacology of tocilizumab across settings. In this study, we adapted a previously developed tocilizumab and soluble IL‐6R (sIL‐6R) population pharmacokinetic model to describe and predict tocilizumab concentrations and sIL‐6R occupancy over time in patients with anti‐CD20 bsAb‐induced CRS following tocilizumab dosing. Using this model, which incorporates target binding and receptor occupancy, we propose a new tocilizumab dosing regimen that is based on quantitative clinical pharmacology, cytokine analyses, and clinical practice patterns in patients with relapsed/refractory B‐cell non‐Hodgkin's lymphoma (R/R B‐NHL) treated with the anti‐CD20 bsAb mosunetuzumab or glofitamab. This schedule (up to two 8 mg/kg intravenous tocilizumab doses per CRS event at least 8 hours apart and a maximum of three doses in 6 weeks) can be used to effectively manage acute CRS induced by anti‐CD20 bsAb in patients with R/R B‐NHL.

01 Sep 2025·BIODRUGS

Bispecific Antibodies in Hematologic Malignancies: Attacking the Frontline

Review

Author: Schatz, Jonathan H ; Trabolsi, Asaad ; Arumov, Artavazd ; Shastri, Toral

Since blinatumomab's approval as the first bispecific antibody (BsAb) in cancer therapy, these immunomodulatory agents have achieved substantial success in lymphoid malignancies. A decade after provisional approval in relapsed settings, blinatumomab became part of first-line induction therapy for patients with B-cell acute lymphoblastic leukemia (B-ALL). Now, six additional BsAbs have FDA approvals for the treatment of B-cell non-Hodgkin's lymphomas and multiple myeloma (MM), achieving high response rates in otherwise refractory scenarios. In lymphoma, epcoritamab, glofitamab, and mosunetuzumab show proof-of-principle for complete remission (CR) without chemotherapy or cell-based treatment. Single-agent remissions do not appear durable, but fortunately, these immunotherapies are readily combined with other treatment modalities. Therefore, their true potential to contribute to cures may be close on the horizon owing to ongoing and future trials. In MM, teclistamab, talquetamab, and elranatamab achieve impressive CR rates in the relapsed setting and similarly, are being investigated in earlier line combinations and in precursor entities such as smoldering myeloma and monoclonal gammopathy of undetermined significance (MGUS). With a unique mechanism of action and continued testing in earlier lines, BsAbs are poised to be among the winners in the race to the frontline treatment of hematologic malignancies.

153

News (Medical) associated with Mosunetuzumab

20 Oct 2025

·firstwordpharma.com

Roche’s Biogen-partnered Gazyva bags FDA nod for lupus nephritis

Roche’s Genentech unit on Monday said the FDA approved a new indication for its CD20-directed antibody Gazyva (obinutuzumab) to treat adults with active lupus nephritis receiving standard therapy of mycophenolate mofetil and glucocorticoids.The therapy — partnered with Biogen in the US — is authorised for administration as four initial doses in the first year, and twice yearly administration thereafter. The agency also okayed a shortened 90-minute infusion time after the first dose for eligible patients with lupus nephritis. “The approval…marks an important step towards a potential new standard of care for lupus nephritis, one that could allow clinicians to offer their patients more effective disease control,” said Levi Garraway, chief medical officer at Genentech.The latest clearance is backed by favourable results from the Phase II NOBILITY trial and Phase III REGENCY trial. Particularly, in the 271-participant REGENCY study, 46.4% of those receiving Gazyva plus standard therapy achieved the primary endpoint of complete renal response versus 33.1% on standard therapy alone. The combination also led to clinically meaningful improvements in complement levels, alongside reductions in anti-dsDNA antibodies, corticosteroid use, and proteinuria.Gazyva already holds approvals in the US and several other countries for haematologic malignancies, including chronic lymphocytic leukaemia and follicular lymphoma. The anti-CD20 antibody — which is marketed as Gazyvaro in the EU — is also awaiting authorisation in the region after having secured a positive opinion from the EU drug advisory panel last week.Key opinion leader Zahi Touma, interviewed by FirstWord last year, said Gazyva could potentially supplant rituximab in lupus nephritis treatment, given its safety profile proves manageable. See – KOL Views Q&A: Roche's Gazyva may finally realise anti-CD20's potential in lupus.Additionally, the treatment is being investigated for additional indications, including systemic lupus erythematosus, membranous nephropathy, idiopathic nephrotic syndrome, and in paediatric and adolescent populations with lupus nephritis.Meanwhile, Roche’s broader lupus pipeline also features two T-cell–engaging bispecifics — CD20xCD3-directed Lunsumio (mosunetuzumab) and CD19xCD3-directed RG6382. For more, read – Vital Signs: Roche’s lupus landgrab.

Phase 3Clinical ResultDrug Approval

30 Sep 2025

·www.einpresswire.com

April - June 2025 | Potential Signals of Serious Risks/New Safety Information Identified by the FDA Adverse Event Reporting System (FAERS)

Acetaminophen-containing products Anaphylactic reaction FDA is evaluating the need for regulatory action. Aptryxol (desvenlafaxine) DaTscan (ioflupane I 123 injection) Desvenlafaxine extended-release tablets Effexor XR (venlafaxine extended-release) capsules Pristiq (desvenlafaxine) extended-release tablets Venlafaxine (venlafaxine hydrochloride) extended-release tablets False positive radioisotope investigation test result potentially secondary to a drug interaction with venlafaxine FDA is evaluating the need for regulatory action. Barium sulfate-containing products Entero Vu 24% (barium sulfate) oral suspension E-Z-Disk (barium sulfate) tablets Liquid E-Z-Paque (barium sulfate) oral suspension Readi-Cat 2 (barium sulfate) oral suspension Readi-Cat 2 Smoothie (barium sulfate) oral suspension Taglitol V (barium sulfate) oral suspension Varibar Honey (barium sulfate) oral suspension Varibar Nectar (barium sulfate) oral suspension Varibar Pudding (barium sulfate) oral paste Varibar Thin Honey (barium sulfate) oral suspension Varibar Thin Liquid (barium sulfate) oral suspension Anaphylactic reaction FDA is evaluating the need for regulatory action. Blincyto (blinatumomab) for injection Columvi (glofitamab-gxbm) injection Elrexfio (elranatamab-bcmm) injection Epkinly (epcoritamab-bysp) injection Imdelltra (tarlatamab-dlle) for injection Kimmtrak (tebentafusp-tebn) injection Lunsumio (mosunetuzumab-axgb) injection Talvey (talquetamab-tgvs) injection Tecvayli (teclistamab-cqyv) injection Progressive multifocal leukoencephalopathy FDA is evaluating the need for regulatory action. BRAF kinase inhibitors Braftovi (encorafenib) capsules Ojemda (tovorafenib) for oral suspension; tablets Tafinlar (dabrafenib) capsules; tablets Zelboraf (vemurafenib) tablets Gingival hypertrophy FDA is evaluating the need for regulatory action. Briumvi (ublituximab-xiiy) injection Kesimpta (ofatumumab) injection Acute hepatic failure The "Warnings and Precautions" section of the labeling was updated in August 2025 to include information about liver injury. Example: Briumvi labeling Briumvi (ublituximab-xiiy) injection Kesimpta (ofatumumab) injection Ocrevus (ocrelizumab) injection Ocrevus Zunovo (ocrelizumab and hyaluronidase-ocsq) injection Central nervous system infection FDA is evaluating the need for regulatory action. Crexont (carbidopa and levodopa) extended-release capsules Dhivy (carbidopa and levodopa) tablets Duopa (carbidopa and levodopa) enteral suspension Rytary (carbidopa and levodopa) extended-release capsules Sinemet (carbidopa and levodopa) tablets Sinemet CR (carbidopa and levodopa) sustained-release tablets Stalevo (carbidopa, levodopa and entacapone) tablets Vyalev (foscarbidopa and foslevodopa) injection Seizure FDA is evaluating the need for regulatory action. Crysvita (burosumab-twza) injection Hypercalcemia The "Dosage and Administration", "Warnings and Precautions" and "Adverse Reactions" sections of the labeling were updated in August 2025 to include information about hypercalcemia. Crysvita labeling Dexmedetomidine-containing products Dexmedetomidine injection Precedex (dexmedetomidine hydrochloride) injection Igalmi (dexmedetomidine) sublingual film Diabetes insipidus FDA is evaluating the need for regulatory action. Dupixent (dupilumab) injection Ocular infections, irritations, and inflammation FDA is evaluating the need for regulatory action. Eprontia (topiramate) oral solution Qudexy XR (topiramate) extended-release capsules Qsymia (phentermine and topiramate) extended-release capsules Topamax (topiramate) tablets Topamax Sprinkle (topiramate) capsules Trokendi XR (topiramate) extended-release capsules Hypersensitivity FDA is evaluating the need for regulatory action. Gavreto (pralsetinib) capsules Chylothorax FDA is evaluating the need for regulatory action. Glucagon-like peptide-1 (GLP-1) receptor agonists Adlyxin (lixisenatide) injection Bydureon (exenatide) for extended-release injectable suspension Bydureon BCise (exenatide extended-release) injectable suspension Byetta (exenatide) injection Mounjaro (tirzepatide) injection Ozempic (semaglutide) injection Rybelsus (semaglutide) tablets Saxenda (liraglutide) injection Soliqua 100/33 (insulin glargine and lixisenatide) injection Trulicity (dulaglutide) injection Victoza (liraglutide) injection Wegovy (semaglutide) injection Xultophy 100/3.6 (insulin degludec and liraglutide) injection Zepbound (tirzepatide) injection Intestinal obstruction and fecal impaction FDA is evaluating the need for regulatory action. Imbruvica (ibrutinib) capsules; tablets; oral suspension Nail and nail bed conditions (excluding infections and infestations) FDA is evaluating the need for regulatory action. MEK inhibitors Avmapki Fakzynja Co-pack (avutometinib capsules; defactinib tablets) Cotellic (cobimetinib) tablets Mekinist (trametinib) tablets; oral solution Mektovi (binimetinib) tablets Koselugo (selumetinib) capsules Gingival hypertrophy FDA is evaluating the need for regulatory action. Neffy (epinephrine nasal spray) Product storage error FDA is evaluating the need for regulatory action. Nurtec ODT (rimegepant) orally disintegrating tablets Zavzpret (zavegepant) nasal spray Anaphylactic reaction The "Contraindications" and "Warnings and Precautions" sections of the labeling were updated in August 2025 to include information about hypersensitivity reactions, including anaphylaxis. Example: Nurtec ODT labeling Rozlytrek (entrectinib) capsules; oral pellets Brugada syndrome FDA is evaluating the need for regulatory action. Sodium-glucose cotransporter-2 (SGLT2) inhibitors Fournier's gangrene FDA is evaluating the need for regulatory action. Teriparatide injection (a particular generic product) Device malfunction FDA is evaluating the need for regulatory action. Vizamyl (flutemetamol F18 injection) Anaphylactic reaction The "Warnings and Precautions" section of the labeling was updated in June 2025 to include information about anaphylaxis and other serious hypersensitivity reactions. Vizamyl labeling Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Drug ApprovalBiosimilar

29 Sep 2025

·pmlive.com

Roche’s Lunsumio receives positive CHMP opinion for follicular lymphoma

Roche has announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of a new subcutaneous (SC) formulation of Lunsumio (mosunetuzumab) to treat adults with relapsed or refractory follicular lymphoma (R/R FL) after two or more lines of systemic therapy. The recommendation follows positive results from the phase 2 GO29781 study, which found pharmacokinetic non-inferiority compared to intravenous (IV) formulations. Lunsumio is a first-in-class bispecific antibody designed to simultaneously target CD20 on B cells and CD3 on T cells. The SC formulation aims to streamline administration and improve patient experience. According to Roche, SC injections can be delivered in around one minute, compared with several hours for intravenous infusion. Treatment duration follows the same six- to 12-month fixed course as the infusion formulation but can be administered in an outpatient setting. Levi Garraway, Roche’s chief medical officer and head of global product development said: “Lunsumio was the first-ever approved CD20xCD3 T-cell engaging bispecific antibody demonstrating high, durable response rates and a favourable safety profile in third-line or later follicular lymphoma. “If approved, the subcutaneous formulation could help to expand the treatment options available, offering people a fixed-duration therapy with a faster treatment administration time.”

Clinical ResultDrug ApprovalPhase 2

100 Deals associated with Mosunetuzumab

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D11463	-	-	DB15434

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Follicular Lymphoma	European Union	Roche Registration GmbH	03 Jun 2022
Follicular Lymphoma	Iceland	Roche Registration GmbH	03 Jun 2022
Follicular Lymphoma	Liechtenstein	Roche Registration GmbH	03 Jun 2022
Follicular Lymphoma	Norway	Roche Registration GmbH	03 Jun 2022

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Aggressive B-Cell Non-Hodgkin Lymphoma	NDA/BLA	Canada	Hoffmann-La Roche Ltd.	01 Jun 2025
Large B-cell lymphoma	Phase 3	Switzerland	Roche Holding AG	23 May 2023
B-cell lymphoma refractory	Phase 3	United States	Hoffmann-La Roche, Inc.	25 Apr 2022
B-cell lymphoma refractory	Phase 3	China	Hoffmann-La Roche, Inc.	25 Apr 2022
B-cell lymphoma refractory	Phase 3	Japan	Hoffmann-La Roche, Inc.	25 Apr 2022
B-cell lymphoma refractory	Phase 3	Argentina	Hoffmann-La Roche, Inc.	25 Apr 2022
B-cell lymphoma refractory	Phase 3	Brazil	Hoffmann-La Roche, Inc.	25 Apr 2022
B-cell lymphoma refractory	Phase 3	Canada	Hoffmann-La Roche, Inc.	25 Apr 2022
B-cell lymphoma refractory	Phase 3	Israel	Hoffmann-La Roche, Inc.	25 Apr 2022
B-cell lymphoma refractory	Phase 3	Mexico	Hoffmann-La Roche, Inc.	25 Apr 2022

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05171647 (SUNMO, Pubmed \| J Clin Oncol)	Phase 3	-	452	Mosunetuzumab plus polatuzumab vedotin	mkcjhkqssx(eydpfyrvqy) = In the Mosun-Pola group, the rate of grade ≥2 cytokine release syndrome and usage of tocilizumab occurred in less than 5% of patients. dhksfxzkfz (dxpcukwztm )	Positive	02 Oct 2025
				Rituximab + Gemcitabine + Oxaliplatin
MITHIC-FL1 (NEWS) Manual	Not Applicable	Follicular Lymphoma First line	-	Mosun SC	vvefzcxxkf(vkvbviskjb) = hxlamwqpaa bnrvhrjrgx (yedrhijsme ) View more	Positive	27 Jun 2025
NEWS Manual	Not Applicable	Mantle cell lymphoma refractory \| Mantle cell lymphoma recurrent	-	Mosun SC + Pola	wtqyxzkaui(euyidtpslz) = cgpijmhtlk oviatahmdr (cffadppmcs ) View more	Positive	27 Jun 2025
NCT05155345 (EULAR2025 \| NEWS) Manual	Phase 1	Systemic Lupus Erythematosus CD20 Positive \| CD86 Positive \| CD4 Positive \| ... View more	15	Mosunetuzumab	umsflzgvut(uktnvsjwyc) = wowdahvdav mxgkmeuics (qtxjysbvmb ) View more	Positive	23 Jun 2025
				MosunetuzumabMosunetuzumab 5mg/45mg	xqwlruoeus(mqtubdoedx) = kydfycreyc bkrfkbmlcn (jqqerqcibz )
NCT05171647 (SUNMO, BusinessWire) Manual	Phase 3	Large B-cell lymphoma	-	Lunsumio® (mosunetuzumab-axgb) + Polivy® (polatuzumab vedotin-piiq)	ntanmsrxux(nbupkjszur) = lyczzzweyp uoulvgdswg (jhccjpkfqy, 5.6 - 17.6) View more	Positive	20 Jun 2025
				Rituxan® (rituximab) + gemcitabine and oxaliplatin (R-GemOx)	ntanmsrxux(nbupkjszur) = bodhuxcjeu uoulvgdswg (jhccjpkfqy, 2.9 - 4.1) View more
NCT05207670 (MorningSun, ASCO2025)	Phase 2	Follicular Lymphoma CD20 \| CD3	102	Mosun SC	mzfzcxdbtn(xaxewlzspu) = yeenkzfpmq mibwgiuscg (ijhwycgwkj, 73.0 - 89.3) View more	Positive	30 May 2025
NCT04792502 (BrUOG-401, ASCO2025)	Phase 2	Follicular Lymphoma First line IL2 \| IL7 \| IFNg ... View more	34	Mosunetuzumab	amuiindcew(liojfqhwvj) = Higher PreTx NK cell abundance significantly correlated with MidTx CR xyxyanmedy (lhyjfixhsc ) View more	Positive	30 May 2025
NCT02500407 (EHA2025) Manual	Phase 2	Recurrent Follicular Lymphoma \| Refractory Follicular Lymphoma	90	Mosunetuzumab (Overall population)	mewslxbidj(msswoybbqn) = agvztcjjgn lnhunstuyp (bmpnktgpsv, 46.4 - NE) View more	Positive	14 May 2025
				Mosunetuzumab (patients with CR)	mewslxbidj(msswoybbqn) = omvtjkkdgp lnhunstuyp (bmpnktgpsv, 46.4 - NE) View more
NCT02500407 (EHA2025) Manual	Phase 2	Recurrent Follicular Lymphoma \| Refractory Follicular Lymphoma Third line	94	Mosunetuzumab SC (overall population)	dacduirfcv(lftxmxfeyu) = ubthijmlep udvzrtvkbx (dxsadvnbsq, 66.7 - 84.7) View more	Positive	14 May 2025
				Mosunetuzumab SC (ann arbor stage III/V)	dacduirfcv(lftxmxfeyu) = qqwoabycdo udvzrtvkbx (dxsadvnbsq, 66.2 - 85.4) View more
NCT05207670 (MorningSun, EHA2025) Manual	Phase 2	Marginal Zone B-Cell Lymphoma First line	36	Mosun SC	hvcicycepq(bbyunbpgew) = smqihhhcap kvpkdmtwjm (yhyeohtnem, 58 - 88) View more	Positive	14 May 2025

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.

login

or

view full example data

Understand key drug designations in just a few clicks with Synapse.